Avadel Pharmaceuticals (AVDL) Stock Forecast, Price Target & Predictions
AVDL Stock Forecast
Avadel Pharmaceuticals stock forecast is as follows: an average price target of $17.80 (represents a 18.27% upside from AVDL’s last price of $15.05) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.
AVDL Price Target
The average price target for Avadel Pharmaceuticals (AVDL) is $17.80 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $30.00 to $9.00. This represents a potential 18.27% upside from AVDL's last price of $15.05.
AVDL Analyst Ratings
According to 8 Wall Street analysts, Avadel Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for AVDL stock is 0 'Strong Buy' (0.00%), 8 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Avadel Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 31, 2024 | Francois Brisebois | Oppenheimer | $30.00 | $12.91 | 132.38% | 99.34% |
| May 09, 2024 | Oren Livnat | H.C. Wainwright | $27.00 | $16.25 | 66.15% | 79.40% |
| Nov 30, 2022 | - | Jefferies | $11.00 | $8.85 | 24.29% | -26.91% |
| Aug 11, 2022 | - | Leerink Partners | $12.00 | $7.14 | 68.07% | -20.27% |
| Aug 10, 2022 | - | Needham | $9.00 | $7.31 | 23.12% | -40.20% |
| Aug 09, 2022 | Chris Howerton | Jefferies | $8.00 | $7.31 | 9.44% | -46.84% |
| May 31, 2022 | - | Needham | $6.00 | $2.50 | 140.00% | -60.13% |
The latest Avadel Pharmaceuticals stock forecast, released on Oct 31, 2024 by Francois Brisebois from Oppenheimer, set a price target of $30.00, which represents a 132.38% increase from the stock price at the time of the forecast ($12.91), and a 99.34% increase from AVDL last price ($15.05).
Avadel Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 1 | 2 |
| Avg Price Target | $30.00 | $30.00 | $28.50 |
| Last Closing Price | $15.05 | $15.05 | $15.05 |
| Upside/Downside | 99.34% | 99.34% | 89.37% |
In the current month, the average price target of Avadel Pharmaceuticals stock is $30.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 99.34% increase as opposed to Avadel Pharmaceuticals's last price of $15.05. This month's average price target is down 0.00% compared to last quarter, and up 5.26% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 31, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Oct 21, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 28, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 11, 2024 | Rodman & Renshaw | - | Buy | Initialise |
| May 09, 2024 | Craig-Hallum | Buy | Buy | Hold |
| May 09, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Mar 05, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Mar 05, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Mar 05, 2024 | Needham | Buy | Buy | Hold |
| Dec 20, 2023 | Needham | Buy | Buy | Hold |
Avadel Pharmaceuticals's last stock rating was published by Oppenheimer on Oct 31, 2024. The company gave AVDL a "Outperform" rating, the same as its previous rate.
Avadel Pharmaceuticals Financial Forecast
Avadel Pharmaceuticals Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | Mar 15 | Mar 14 | Mar 13 | Mar 12 | Mar 11 | Mar 10 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.50M | $10.09M | $12.24M | $10.99M | $14.23M | $17.55M | $16.44M | $33.29M | $52.51M | $36.22M | $32.73M | $9.18M | $5.14M | $7.36M | $6.76M | $8.09M |
| Avg Forecast | $107.10M | $99.50M | $94.90M | $85.70M | $82.48M | $77.09M | $70.86M | $62.79M | $56.05M | $48.43M | $37.47M | $25.89M | $18.19M | $5.12M | $361.33K | $7.92M | $9.52M | $9.60M | $10.25M | $10.50M | $13.88M | $28.09M | $889.95K | $33.80M | $36.95M | $16.52M | $4.83M | $5.26M | $4.57M | $5.60M |
| High Forecast | $107.10M | $99.50M | $94.90M | $85.70M | $82.48M | $77.09M | $70.86M | $62.79M | $56.05M | $49.68M | $37.47M | $25.89M | $19.85M | $5.12M | $361.33K | $7.92M | $9.52M | $9.60M | $10.25M | $10.50M | $13.88M | $33.71M | $1.07M | $40.56M | $44.34M | $19.82M | $5.79M | $6.31M | $5.48M | $6.72M |
| Low Forecast | $107.10M | $99.50M | $94.90M | $85.70M | $82.48M | $77.09M | $70.86M | $62.79M | $56.05M | $46.50M | $37.47M | $25.89M | $15.53M | $5.12M | $361.33K | $7.92M | $9.52M | $9.60M | $10.25M | $10.50M | $13.88M | $22.47M | $711.96K | $27.04M | $29.56M | $13.21M | $3.86M | $4.21M | $3.65M | $4.48M |
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 3 | 6 | 3 | 3 | 9 | 6 | 4 | 4 | 7 | 4 | 11 | 9 | 12 | 13 | 15 | 19 | 13 | 9 | 14 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.14% | 1.27% | 1.29% | 1.15% | 1.39% | 1.67% | 1.18% | 1.19% | 59.00% | 1.07% | 0.89% | 0.56% | 1.06% | 1.40% | 1.48% | 1.44% |
Avadel Pharmaceuticals's average Quarter revenue forecast for Sep 23 based on 3 analysts is $5.12M, with a low forecast of $5.12M, and a high forecast of $5.12M. AVDL's average Quarter revenue forecast represents a 242.57% increase compared to the company's last Quarter revenue of $1.50M (Jun 23).
Avadel Pharmaceuticals EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | Mar 15 | Mar 14 | Mar 13 | Mar 12 | Mar 11 | Mar 10 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 3 | 6 | 3 | 3 | 9 | 6 | 4 | 4 | 7 | 4 | 11 | 9 | 12 | 13 | 15 | 19 | 13 | 9 | 14 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-49.54M | $39.92M | $-6.73M | $-7.75M | $-2.88M | $-3.02M | $-9.96M | $-10.98M | $35.55M | $6.55M | $25.78M | $-20.20M | $-9.47M | $762.00K | $-3.88M | $-2.65M |
| Avg Forecast | $-5.19M | $-4.82M | $-4.60M | $-4.15M | $-3.99M | $-3.73M | $-3.43M | $-3.04M | $-2.71M | $-2.35M | $-1.81M | $-1.25M | $-880.89K | $-248.22K | $-17.50K | $-383.38K | $-11.61M | $-464.96K | $-496.44K | $-508.55K | $-12.81M | $-8.95M | $-43.10K | $18.12M | $29.11M | $-36.36M | $-8.90M | $544.28K | $-2.01M | $-1.84M |
| High Forecast | $-5.19M | $-4.82M | $-4.60M | $-4.15M | $-3.99M | $-3.73M | $-3.43M | $-3.04M | $-2.71M | $-2.25M | $-1.81M | $-1.25M | $-752.37K | $-248.21K | $-17.50K | $-383.38K | $-9.29M | $-464.96K | $-496.44K | $-508.55K | $-10.25M | $-7.16M | $-34.48K | $21.74M | $34.93M | $-29.09M | $-7.12M | $653.14K | $-1.61M | $-1.47M |
| Low Forecast | $-5.19M | $-4.82M | $-4.60M | $-4.15M | $-3.99M | $-3.73M | $-3.43M | $-3.04M | $-2.71M | $-2.41M | $-1.81M | $-1.25M | $-961.34K | $-248.22K | $-17.50K | $-383.38K | $-13.93M | $-464.96K | $-496.44K | $-508.55K | $-15.37M | $-10.74M | $-51.72K | $14.50M | $23.29M | $-43.63M | $-10.67M | $435.43K | $-2.41M | $-2.20M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2830.91% | -104.13% | 0.58% | 16.67% | 5.80% | 5.94% | 0.78% | 1.23% | -824.75% | 0.36% | 0.89% | 0.56% | 1.06% | 1.40% | 1.93% | 1.44% |
3 analysts predict AVDL's average Quarter EBITDA for Jun 23 to be $-17.50K, with a high of $-17.50K and a low of $-17.50K. This is -100.04% lower than Avadel Pharmaceuticals's previous annual EBITDA (Jun 20) of $39.92M.
Avadel Pharmaceuticals Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | Mar 15 | Mar 14 | Mar 13 | Mar 12 | Mar 11 | Mar 10 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 3 | 6 | 3 | 3 | 9 | 6 | 4 | 4 | 7 | 4 | 11 | 9 | 12 | 13 | 15 | 19 | 13 | 9 | 14 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-64.43M | $30.87M | $-865.00K | $-2.74M | $-8.86M | $-8.61M | $-13.02M | $-12.24M | $25.91M | $-6.38M | $11.65M | $-26.64M | $-8.83M | $12.00K | $-4.93M | $-4.02M |
| Avg Forecast | $33.65M | $27.88M | $25.00M | $19.23M | $22.15M | $13.46M | $7.93M | $1.44M | $-1.26M | $-7.85M | $-17.20M | $-22.36M | $-27.04M | $-35.76M | $-34.48M | $-16.51M | $-1.49M | $-25.00M | $-15.38M | $-31.73M | $-16.74M | $-9.97M | $1.42B | $-17.63M | $13.15M | $-47.95M | $-8.29M | $8.57K | $-2.55M | $-2.79M |
| High Forecast | $33.65M | $27.88M | $25.00M | $19.23M | $22.15M | $13.46M | $7.93M | $1.44M | $-1.26M | $-2.62M | $-17.20M | $-22.36M | $-22.21M | $-35.76M | $-34.48M | $-16.51M | $-1.19M | $-25.00M | $-15.38M | $-31.73M | $-13.39M | $-7.98M | $1.71B | $-14.10M | $15.78M | $-38.36M | $-6.64M | $10.29K | $-2.04M | $-2.23M |
| Low Forecast | $33.65M | $27.88M | $25.00M | $19.23M | $22.15M | $13.46M | $7.93M | $1.44M | $-1.26M | $-14.40M | $-17.20M | $-22.36M | $-32.84M | $-35.76M | $-34.48M | $-16.51M | $-1.79M | $-25.00M | $-15.38M | $-31.73M | $-20.08M | $-11.96M | $1.14B | $-21.15M | $10.52M | $-57.54M | $-9.95M | $6.86K | $-3.07M | $-3.34M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.87% | -1.87% | 0.58% | 0.11% | 0.58% | 0.27% | 0.78% | 1.23% | 0.02% | 0.36% | 0.89% | 0.56% | 1.06% | 1.40% | 1.93% | 1.44% |
Avadel Pharmaceuticals's average Quarter net income forecast for Jun 23 is $-34.48M, with a range of $-34.48M to $-34.48M. AVDL's average Quarter net income forecast represents a -211.67% decrease compared to the company's last Quarter net income of $30.87M (Jun 20).
Avadel Pharmaceuticals SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | Mar 15 | Mar 14 | Mar 13 | Mar 12 | Mar 11 | Mar 10 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 3 | 6 | 3 | 3 | 9 | 6 | 4 | 4 | 7 | 4 | 11 | 9 | 12 | 13 | 15 | 19 | 13 | 9 | 14 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $46.78M | $7.09M | $7.91M | $7.66M | $5.32M | $6.76M | $10.45M | $24.49M | $11.81M | $9.46M | $4.46M | $3.56M | $2.49M | $5.18M | $2.53M | $2.93M |
| Avg Forecast | $199.69M | $185.52M | $176.94M | $159.79M | $153.78M | $143.73M | $132.12M | $117.08M | $104.52M | $90.31M | $69.86M | $48.28M | $33.91M | $9.56M | $673.72K | $14.76M | $17.75M | $17.90M | $19.11M | $19.58M | $13.43M | $19.95M | $1.66M | $26.15M | $5.04M | $6.40M | $2.34M | $3.70M | $1.31M | $2.03M |
| High Forecast | $199.69M | $185.52M | $176.94M | $159.79M | $153.78M | $143.73M | $132.12M | $117.08M | $104.52M | $92.63M | $69.86M | $48.28M | $37.01M | $9.56M | $673.72K | $14.76M | $17.75M | $17.90M | $19.11M | $19.58M | $16.12M | $23.94M | $1.99M | $31.38M | $6.05M | $7.68M | $2.81M | $4.44M | $1.57M | $2.43M |
| Low Forecast | $199.69M | $185.52M | $176.94M | $159.79M | $153.78M | $143.73M | $132.12M | $117.08M | $104.52M | $86.70M | $69.86M | $48.28M | $28.96M | $9.56M | $673.72K | $14.76M | $17.75M | $17.90M | $19.11M | $19.58M | $10.74M | $15.96M | $1.33M | $20.92M | $4.03M | $5.12M | $1.87M | $2.96M | $1.05M | $1.62M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 69.43% | 0.48% | 0.45% | 0.43% | 0.28% | 0.35% | 0.78% | 1.23% | 7.12% | 0.36% | 0.89% | 0.56% | 1.06% | 1.40% | 1.93% | 1.44% |
Avadel Pharmaceuticals's average Quarter SG&A projection for Sep 23 is $9.56M, based on 3 Wall Street analysts, with a range of $9.56M to $9.56M. The forecast indicates a -79.57% fall compared to AVDL last annual SG&A of $46.78M (Jun 23).
Avadel Pharmaceuticals EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | Mar 15 | Mar 14 | Mar 13 | Mar 12 | Mar 11 | Mar 10 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 3 | 6 | 3 | 3 | 9 | 6 | 4 | 4 | 7 | 4 | 11 | 9 | 12 | 13 | 15 | 19 | 13 | 9 | 14 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.83 | $0.57 | $-0.02 | $-0.07 | $-0.24 | $-0.23 | $-0.35 | $-0.32 | $0.63 | $-0.15 | $0.29 | $-0.94 | $-0.35 | - | $-0.20 | $-0.17 |
| Avg Forecast | $0.35 | $0.29 | $0.26 | $0.20 | $0.23 | $0.14 | $0.08 | $0.01 | $-0.01 | $-0.08 | $-0.18 | $-0.23 | $-0.28 | $-0.37 | $-0.36 | $-0.17 | $-0.26 | $-0.26 | $-0.16 | $-0.33 | $-0.40 | $-0.22 | $-0.55 | $0.39 | $0.35 | $-0.27 | $-0.31 | $-0.05 | $-0.06 | $-0.09 |
| High Forecast | $0.35 | $0.29 | $0.26 | $0.20 | $0.23 | $0.14 | $0.08 | $0.01 | $-0.01 | $-0.03 | $-0.18 | $-0.23 | $-0.23 | $-0.37 | $-0.36 | $-0.17 | $-0.26 | $-0.26 | $-0.16 | $-0.33 | $-0.40 | $-0.18 | $-0.44 | $0.46 | $0.42 | $-0.22 | $-0.25 | $-0.04 | $-0.05 | $-0.07 |
| Low Forecast | $0.35 | $0.29 | $0.26 | $0.20 | $0.23 | $0.14 | $0.08 | $0.01 | $-0.01 | $-0.15 | $-0.18 | $-0.23 | $-0.34 | $-0.37 | $-0.36 | $-0.17 | $-0.26 | $-0.26 | $-0.16 | $-0.33 | $-0.40 | $-0.26 | $-0.66 | $0.31 | $0.28 | $-0.32 | $-0.37 | $-0.06 | $-0.07 | $-0.11 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.31% | -3.32% | 0.08% | 0.27% | 1.50% | 0.70% | 0.87% | 1.45% | -1.15% | -0.38% | 0.83% | 3.48% | 1.13% | -0.01% | 3.33% | 1.84% |
According to 3 Wall Street analysts, Avadel Pharmaceuticals's projected average Quarter EPS for Jun 23 is $-0.36, with a low estimate of $-0.36 and a high estimate of $-0.36. This represents a -162.91% decrease compared to AVDL previous annual EPS of $0.57 (Jun 20).
Avadel Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| EVOK | Evoke Pharma | $5.80 | $18.00 | 210.34% | Buy |
| ASRT | Assertio | $1.03 | $2.88 | 179.61% | Buy |
| IRWD | Ironwood Pharmaceuticals | $4.19 | $11.67 | 178.52% | Buy |
| DVAX | Dynavax | $11.78 | $24.50 | 107.98% | Buy |
| AQST | Aquestive Therapeutics | $5.52 | $9.50 | 72.10% | Buy |
| ANIP | ANI Pharmaceuticals | $58.19 | $79.00 | 35.76% | Buy |
| ALKS | Alkermes | $26.47 | $34.38 | 29.88% | Hold |
| NBIX | Neurocrine Biosciences | $122.21 | $147.70 | 20.86% | Buy |
| AVDL | Avadel Pharmaceuticals | $15.05 | $17.80 | 18.27% | Buy |
| LFCR | Lifecore Biomedical | $5.88 | $6.50 | 10.54% | Buy |
| ITCI | Intra-Cellular Therapies | $86.54 | $94.50 | 9.20% | Buy |
| DCPH | Deciphera Pharmaceuticals | $25.59 | $26.32 | 2.85% | Hold |
| AMRX | Amneal Pharmaceuticals | $8.49 | $8.00 | -5.77% | Buy |
| AGRX | Agile Therapeutics | $1.51 | $1.00 | -33.77% | Buy |
AVDL Forecast FAQ
Is Avadel Pharmaceuticals a good buy?
Yes, according to 8 Wall Street analysts, Avadel Pharmaceuticals (AVDL) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 8 'Buy' recommendations, accounting for 100.00% of AVDL's total ratings.
What is AVDL's price target?
Avadel Pharmaceuticals (AVDL) average price target is $17.8 with a range of $9 to $30, implying a 18.27% from its last price of $15.05. The data is based on 8 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Avadel Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for AVDL stock, the company can go up by 18.27% (from the last price of $15.05 to the average price target of $17.8), up by 99.34% based on the highest stock price target, and down by -40.20% based on the lowest stock price target.
Can Avadel Pharmaceuticals stock reach $20?
AVDL's highest twelve months analyst stock price target of $30 supports the claim that Avadel Pharmaceuticals can reach $20 in the near future.
What is Avadel Pharmaceuticals's current price target trend?
1 Wall Street analyst forecast a $30 price target for Avadel Pharmaceuticals (AVDL) this month, up 99.34% from its last price of $15.05. Compared to the last 3 and 12 months, the average price target increased by 99.34% and increased by 89.37%, respectively.
What are Avadel Pharmaceuticals's analysts' financial forecasts?
Avadel Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $293.21M (high $293.21M, low $293.21M), average EBITDA is $-14.201M (high $-14.201M, low $-14.201M), average net income is $44.99M (high $44.99M, low $44.99M), average SG&A $546.71M (high $546.71M, low $546.71M), and average EPS is $0.468 (high $0.468, low $0.468). AVDL's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $387.2M (high $387.2M, low $387.2M), average EBITDA is $-18.754M (high $-18.754M, low $-18.754M), average net income is $105.77M (high $105.77M, low $105.77M), average SG&A $721.95M (high $721.95M, low $721.95M), and average EPS is $1.1 (high $1.1, low $1.1).
Did the AVDL's actual financial results beat the analysts' financial forecasts?
Based on Avadel Pharmaceuticals's last annual report (Dec 2019), the company's revenue was $59.22M, beating the average analysts forecast of $44.22M by 33.89%. Apple's EBITDA was $-14.34M, beating the average prediction of $-14.277M by 0.44%. The company's net income was $-33.226M, missing the average estimation of $-88.851M by -62.60%. Apple's SG&A was $30.18M, missing the average forecast of $70.02M by -56.89%. Lastly, the company's EPS was $-0.89, missing the average prediction of $-1.15 by -22.61%. In terms of the last quarterly report (Jun 2023), Avadel Pharmaceuticals's revenue was $1.5M, beating the average analysts' forecast of $361.33K by 314.02%. The company's EBITDA was $-49.541M, beating the average prediction of $-17.5K by 282991.43%. Avadel Pharmaceuticals's net income was $-64.432M, beating the average estimation of $-34.477M by 86.88%. The company's SG&A was $46.78M, beating the average forecast of $673.72K by 6843.25%. Lastly, the company's EPS was $-0.83, beating the average prediction of $-0.359 by 131.48%